GSK-3 as potential target for therapeutic intervention in cancer
Metrics: PDF 2282 views | HTML 1083 views | ?
James A. McCubrey1, Linda S. Steelman1, Fred E. Bertrand2, Nicole M. Davis1, Melissa Sokolosky1, Steve L. Abrams1, Giuseppe Montalto3, Antonino B. D’Assoro4, Massimo Libra5, Ferdinando Nicoletti5, Roberta Maestro6, Jorg Basecke7,8, Dariusz Rakus9, Agnieszka Gizak9 Zoya Demidenko10, Lucio Cocco11, Alberto M. Martelli11 and Melchiorre Cervello12
1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC, USA
2 Department of Oncology, Brody School of Medicine at East Carolina University Greenville, NC, USA
3 Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy
4 Department of Medical Oncology, Mayo Clinic Cancer Center, Rochester, MN, USA
5 Department of Bio-Medical Sciences, University of Catania, Catania, Italy
6 Experimental Oncology 1, CRO IRCCS, National Cancer Institute, Aviano, Pordenone, Italy.
7 Department of Medicine, University of Göttingen, Göttingen, Germany
8 Sanct-Josef-Hospital Cloppenburg, Department of Hematology and Oncology, Cloppenburg, Germany
9 Department of Animal Molecular Physiology, Institute of Experimental Biology, Wroclaw University, Wroclaw, Poland
10 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
11 Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy
12 Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy”, Palermo, Italy
James A. McCubrey, email:
Keywords: GSK-3, cancer stem cells, Wnt/beta-catenin, PI3K, Akt, mTOR, Hedgehog, Notch, Targeted Therapy, Therapy Resistance, Mutations, Rapamycin
Received: April 24, 2014 Accepted: May 28, 2014 Published: May 28, 2014
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer’s disease, Parkinson’s disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.
James A. McCubrey
Primary Contact _
Linda S. Steelman
Fred E. Bertrand
Nicole M. Davis
Steve L. Abrams
Antonino B. D’Assoro
Alberto M. Martelli
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.